Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

or 1.8 mg liraglutide. [O]ral semaglutide 14 mg (or flexible dosing, in PIONEER 7) was generally more effective at improving multiple cardiometabolic risk factors — including HbA 1c, [body weight], ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2 ...

The Boston Celtics kick off a two-game homestand against the Miami Heat on Wednesday. Boston has won nine games in a row and is second (56-19) in the East. Meanwhile, the Heat are struggling in ...

The average percentage of body weight change from baseline (starting weight) to one year was: 5.1 percent with semaglutide 2.2 percent with liraglutide A 2022 study found the dose matters ...

Lexaria Bioscience (LEXX) announced that dosing has begun as scheduled in its human study GLP-1-H25-5 that is comparing oral DehydraTECH-liraglutide ... to the oral semaglutide and injectable ...

Semaglutide increased maximum walking distance by 13% compared ... extension for Ozempic based on the results of the STRIDE trial. A decision by the Food and Drug Administration is expected some time ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with type 2 diabetes. While some GLP-1 agonists are used for weight loss in people ...